Tetra Therapeutics is developing a platform of drug products to treat cognitive impairment. The Apjohn Group was not involved with founding Tetra, but advised in the formation of a special purpose investment entity to co-lead a $5 million Series A round of financing with the Grand Angels. Included in the full Series A investor list are Dolby Family Ventures, The Alzheimer’s Drug Discovery Foundation, and other private investors. In 2020, Tetra was acquired by Shionogi & Co. LTD., a Japanese pharmaceutical company, for $500 million. Shionogi recently launched a Phase 2b/3 trial of BPN14770 for Fragile X. For more information please visit shionogi.com.